Loperamide is suitable for long-term therapy, provided there is an established diagnosis, as it has fewer CNS side-effects and less potential for dependence.

Treatment of infective diarrhoea is included in the local Management of Infection guidance.

LOPERAMIDE - (First line)

Important: Therapy notes

MHRA advice: Loperamide (Imodium): reports of serious cardiac adverse reactions with high doses of loperamide associated with abuse or misuse (September 2017) (www.gov.uk)

  • For faecal incontinence off-label initially 500 micrograms daily (unlicensed syrup 1mg/5mL) then increasing the dose until desired stool consistency is reached.  Maximum 16mg daily in divided doses.  Doses 2mg and above should be with the licensed capsule.  

Important: Formulation and dosage details

Formulation:

Capsules 2mg

Dosage:

4mg initially followed by 2mg after each loose stool for up to 5 days, maximum 16mg daily.

Important: Formulation and dosage details

Formulation:

Orodispersible tablets 2mg (specialist initiation)

Dosage:

Orodispersible tablets are for specialist initiation in patients who have had colectomies and who have either an end ileostomy or have an ileoanal J-pouch.

CODEINE

Important: Therapy notes

Important: Formulation and dosage details

Formulation:

Tablets 15mg, 30mg

Dosage:

30mg 3 to 4 times daily.

Editorial Information

Document Id: F217